Thu, Nov 20, 2025 3:43 PM

Egis Pharmaceuticals PLC inaugurates new active ingredient manufacturing plant

Egis Pharmaceuticals PLC has inaugarated one of the largest active pharmaceutical ingredient (API) investments in its 112-year history in Budapest. The new HUF 30 billion plant, financed from the company’s own resources, will produce the active ingredient of a globally market-leading medicine, featuring numerous technological innovations.
Egis World

Egis Pharmaceuticals PLC inaugurates new active ingredient manufacturing plant

Egis Pharmaceuticals PLC has inaugarated one of the largest active pharmaceutical ingredient (API) investments in its 112-year history in Budapest. The new HUF 30 billion plant, financed from the company’s own resources, will produce the active ingredient of a globally market-leading medicine, featuring numerous technological innovations.
Thu, Nov 20, 2025 3:43 PM
Author:
Thu, Nov 20, 2025 3:43 PM
Author:

In recent decades, a general trend in the European pharmaceutical industry has been the decline of API manufacturing. Egis, however, has been remained committed to API production and, in this spirit, has renewed this line of activity in several stages over the past 12 years. The current HUF 30 billion brownfield investment in Kőbánya is unique in that its “twin plant” in Normandy was inaugurated only recently. The two technologically identical facilities manufacture the active ingredient of the Servier Group’s medicine recommended for the treatment of venous diseases. Together, the two plants provide the required production capacity.

 

Thanks to these plants, the production volume of this active ingredient will double. Due to the most advanced technologies and more efficient manufacturing processes, the facilities can meet the growing demand driven by increasing patient needs more efficiently and with a smaller environmental footprint.

“We are convinced that API manufacturing contributes significantly not only to competitiveness but also to security of supply,” said Csaba Poroszlai, CEO of Egis Pharmaceuticals PLC. “Egis is a vertically integrated European company – meaning that here in Europe we conduct research and development and manufacture both pharmaceutical active ingredients and finished products, which we then market worldwide. Moreover, we have not only retained our API production, but in the past decade completely renewed and modernised it; even at times when global trends dictated the opposite and many other manufacturers shut down this activity or relocated it outside Europe.” He stressed that the newly inaugurated facility provides Egis with API manufacturing capacities that secure the foundations for long-term development, as they further strengthen the company’s competitiveness and enable the pharmaceutical company to actively contribute to enhancing security of supply in Europe.

 

“This investment is forward-looking not only for the company but for the entire European pharmaceutical manufacturing sector,” underlined Olivér Várhelyi, European Commissioner for Health and Animal Welfare. He also emphasised: for the competitiveness of the entire European pharmaceutical industry it is of key importance that API manufacturing capacities on our continent be rebuilt and further developed. “Only in this way can we make supply chains safer and guarantee patients timely access to high-quality medicines in all Member States of the Union.”

Over the four-year project, a modern manufacturing plant with multiple technological levels has been built, applying the most advanced technical and quality assurance solutions.

 

Beyond the newly inaugurated Budapest investment, Egis is continuously strengthening its production capacities and market presence. This summer, the company announced that it would further modernise its site in Körmend with a development worth more than HUF 14 billion, where since 2018 nearly HUF 29 billion of investments creating jobs have been implemented with state support.

 

For further information about the new facility and the Egis' active ingredient production, please click here.

Related articles from Egis Magazine
 

Egis Pharmaceuticals PLC and the Faculty of Mechanical Engineering at BME Sign Cooperation Agreement
Sep. 01.
More
 

Egis Invests Over HUF 14 Billion in Körmend Site Development
Jul. 28.
More
 

Egis Commits to Voluntary Price Cap
Jun. 12.
More

Submit
Submit

Cookie Settings

Egis’s website uses cookies to run our website, improve the user experience and monitor the activities. You can customize the use of the cookies by adapting the settings.

Cookies necessary for basic functioning

These cookies ensure the appropriate functioning of the website, facilitate its use and collect information on its use without identifying visitors.

Functional cookies

In order to enhance the user experience, we use cookies which record the use of certain functions of the website, thus enabling users to have the same settings at the time of their next visit.

Cookies for statistical purposes

They provide statistical data on the performance of the website (such as number of page loads, average time spent on the website) in order to collect data for the operator of the website on the website usage patterns of users. These cookies do not identify visitors, information collected by them relate to the number of subpages visited by the user, the length of each session, the types of error messages, etc. Cookies for statistical purposes are automatically placed on the user’s devices during browsing, and you can delete such cookies in the browser settings.
Details
I Agree
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox